Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Repeatability of FDG PET/CT metrics assessed in free breathing and deep inspiration breath hold in lung cancer patients.

Nygård L, Aznar MC, Fischer BM, Persson GF, Christensen CB, Andersen FL, Josipovic M, Langer SW, Kjær A, Vogelius IR, Bentzen SM.

Am J Nucl Med Mol Imaging. 2018 Apr 25;8(2):127-136. eCollection 2018.

2.

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).

Ali AS, Grönberg M, Langer SW, Ladekarl M, Hjortland GO, Vestermark LW, Österlund P, Welin S, Grønbæk H, Knigge U, Sorbye H, Janson ET.

Med Oncol. 2018 Mar 6;35(4):47. doi: 10.1007/s12032-018-1103-x.

3.

A Competing Risk Model of First Failure Site after Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

Nygård L, Vogelius IR, Fischer BM, Kjær A, Langer SW, Aznar MC, Persson GF, Bentzen SM.

J Thorac Oncol. 2018 Apr;13(4):559-567. doi: 10.1016/j.jtho.2017.12.011.

PMID:
29355615
4.

Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine.

Risum S, Knigge U, Langer SW.

Clin Case Rep. 2017 Nov 7;5(12):2085-2087. doi: 10.1002/ccr3.1262. eCollection 2017 Dec.

5.

Reproducibility of MR-Based Attenuation Maps in PET/MRI and the Impact on PET Quantification in Lung Cancer.

Olin A, Ladefoged CN, Langer NH, Keller SH, Löfgren J, Hansen AE, Kjær A, Langer SW, Fischer BM, Andersen FL.

J Nucl Med. 2018 Jun;59(6):999-1004. doi: 10.2967/jnumed.117.198853. Epub 2017 Nov 9.

PMID:
29123008
6.

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.

Ali AS, Grönberg M, Federspiel B, Scoazec JY, Hjortland GO, Grønbæk H, Ladekarl M, Langer SW, Welin S, Vestermark LW, Arola J, Österlund P, Knigge U, Sorbye H, Grimelius L, Janson ET.

PLoS One. 2017 Nov 7;12(11):e0187667. doi: 10.1371/journal.pone.0187667. eCollection 2017.

7.

Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.

Galleberg RB, Knigge U, Tiensuu Janson E, Vestermark LW, Haugvik SP, Ladekarl M, Langer SW, Grønbæk H, Österlund P, Hjortland GO, Assmus J, Tang L, Perren A, Sorbye H.

Eur J Surg Oncol. 2017 Sep;43(9):1682-1689. doi: 10.1016/j.ejso.2017.04.010. Epub 2017 May 4.

PMID:
28522174
8.

Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy.

Guldbrandsen KF, Hendel HW, Langer SW, Fischer BM.

Diagnostics (Basel). 2017 Apr 21;7(2). pii: E23. doi: 10.3390/diagnostics7020023. Review.

9.

Primary pulmonary adenocarcinoma in a 16-year-old boy - a five-year follow-up.

Måreng AS, Langer SW, Bodtger U.

Eur Clin Respir J. 2016 Nov 7;3:32633. doi: 10.3402/ecrj.v3.32633. eCollection 2016.

10.

Changes in Health-Related Quality of Life During Rehabilitation in Patients With Operable Lung Cancer: A Feasibility Study (PROLUCA).

Sommer MS, Trier K, Vibe-Petersen J, Christensen KB, Missel M, Christensen M, Larsen KR, Langer SW, Hendriksen C, Clementsen PF, Pedersen JH, Langberg H.

Integr Cancer Ther. 2018 Jun;17(2):388-400. doi: 10.1177/1534735416668258. Epub 2016 Oct 3.

11.

[Cardiovascular complications following thoracic radiotherapy in patients with cancer].

Nielsen KM, Borchsenius JI, Offersen BV, Langer SW, Nielsen HM, Rasmussen VG, Hansen PR.

Ugeskr Laeger. 2016 Sep 26;178(39). pii: V05160362. Danish.

PMID:
27697124
12.

Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.

Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A.

J Nucl Med. 2017 Mar;58(3):451-457. doi: 10.2967/jnumed.116.180430. Epub 2016 Sep 22.

13.

Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients.

Johnbeck CB, Knigge U, Langer SW, Loft A, Berthelsen AK, Federspiel B, Binderup T, Kjaer A.

J Nucl Med. 2016 Dec;57(12):1851-1857. Epub 2016 Jul 28.

14.

Perioperative Rehabilitation in Operable Lung Cancer Patients (PROLUCA): A Feasibility Study.

Sommer MS, Trier K, Vibe-Petersen J, Missel M, Christensen M, Larsen KR, Langer SW, Hendriksen C, Clementsen PF, Pedersen JH, Langberg H.

Integr Cancer Ther. 2016 Dec;15(4):455-466. Epub 2016 May 4.

15.

(68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2.

Olsen IH, Langer SW, Federspiel BH, Oxbøl J, Loft A, Berthelsen AK, Mortensen J, Oturai P, Knigge U, Kjær A.

Am J Nucl Med Mol Imaging. 2016 Jan 28;6(1):59-72. eCollection 2016.

16.

Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review.

Ilett EE, Langer SW, Olsen IH, Federspiel B, Kjær A, Knigge U.

Diagnostics (Basel). 2015 Apr 8;5(2):119-76. doi: 10.3390/diagnostics5020119. Review.

17.

Early lesion-specific (18)F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer.

Nygård L, Vogelius IR, Fischer BM, Klausen TL, Langer SW, Lonsdale MN, Persson GF, Bentzen SM.

Radiother Oncol. 2016 Mar;118(3):460-4. doi: 10.1016/j.radonc.2016.01.009. Epub 2016 Jan 21.

PMID:
26806265
18.

Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases.

Langer SW, Ringholm L, Dali CI, Petersen RH, Rasmussen ÅK, Gerdes AM, Federspiel B, Knigge UP.

Case Rep Med. 2015;2015:265786. doi: 10.1155/2015/265786. Epub 2015 Dec 22.

19.

Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study.

Haugvik SP, Janson ET, Österlund P, Langer SW, Falk RS, Labori KJ, Vestermark LW, Grønbæk H, Gladhaug IP, Sorbye H.

Ann Surg Oncol. 2016 May;23(5):1721-8. doi: 10.1245/s10434-015-5013-2. Epub 2015 Dec 17.

PMID:
26678407
20.

64Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with 68Ga-DOTATOC in 60 Patients.

Malmberg C, Ripa RS, Johnbeck CB, Knigge U, Langer SW, Mortensen J, Oturai P, Loft A, Hag AM, Kjær A.

J Nucl Med. 2015 Dec;56(12):1895-900. doi: 10.2967/jnumed.115.161216. Epub 2015 Oct 1.

21.

Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art.

Tabaksblat EM, Langer SW, Knigge U, Grønbæk H, Mortensen J, Petersen RH, Federspiel BH, Ladekarl M.

Acta Oncol. 2016;55(1):3-14. doi: 10.3109/0284186X.2015.1067715. Epub 2015 Jul 30. Review.

PMID:
26223571
22.

64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.

Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, Berthelsen AK, Langer SW, Rasmussen P, Elema D, von Benzon E, Højgaard L, Kjaer A.

J Nucl Med. 2015 Jun;56(6):847-54. doi: 10.2967/jnumed.115.156539. Epub 2015 May 7.

23.
24.

The Impact of a Multidimensional Exercise Intervention on Physical and Functional Capacity, Anxiety, and Depression in Patients With Advanced-Stage Lung Cancer Undergoing Chemotherapy.

Quist M, Adamsen L, Rørth M, Laursen JH, Christensen KB, Langer SW.

Integr Cancer Ther. 2015 Jul;14(4):341-9. doi: 10.1177/1534735415572887. Epub 2015 Mar 22.

PMID:
25800229
25.

Goblet cell carcinoids: characteristics of a Danish cohort of 83 patients.

Olsen IH, Holt N, Langer SW, Hasselby JP, Grønbæk H, Hillingsø J, Mahmoud M, Ladekarl M, Iversen LH, Kjær A, Federspiel BH, Knigge U.

PLoS One. 2015 Feb 11;10(2):e0117627. doi: 10.1371/journal.pone.0117627. eCollection 2015.

26.

Dexrazoxane for the treatment of chemotherapy-related side effects.

Langer SW.

Cancer Manag Res. 2014 Sep 15;6:357-63. doi: 10.2147/CMAR.S47238. eCollection 2014. Review.

27.

Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomas.

Olsen IH, Knigge U, Federspiel B, Hansen CP, Skov A, Kjær A, Langer SW.

J Cancer. 2014 Aug 1;5(8):628-32. doi: 10.7150/jca.9409. eCollection 2014.

28.

Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.

Janson ET, Sorbye H, Welin S, Federspiel B, Grønbæk H, Hellman P, Ladekarl M, Langer SW, Mortensen J, Schalin-Jäntti C, Sundin A, Sundlöv A, Thiis-Evensen E, Knigge U.

Acta Oncol. 2014 Oct;53(10):1284-97. doi: 10.3109/0284186X.2014.941999. Epub 2014 Aug 20. Review.

PMID:
25140861
29.

Perioperative rehabilitation in operation for lung cancer (PROLUCA) - rationale and design.

Sommer MS, Trier K, Vibe-Petersen J, Missel M, Christensen M, Larsen KR, Langer SW, Hendriksen C, Clementsen P, Pedersen JH, Langberg H.

BMC Cancer. 2014 Jun 4;14:404. doi: 10.1186/1471-2407-14-404.

30.

PET/CT in therapy evaluation of patients with lung cancer.

Langer NH, Christensen TN, Langer SW, Kjaer A, Fischer BM.

Expert Rev Anticancer Ther. 2014 May;14(5):595-620. doi: 10.1586/14737140.2014.883280. Epub 2014 Apr 7.

PMID:
24702537
32.

Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.

Olsen IH, Sørensen JB, Federspiel B, Kjaer A, Hansen CP, Knigge U, Langer SW.

ScientificWorldJournal. 2012;2012:170496. doi: 10.1100/2012/170496. Epub 2012 Aug 22.

33.

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U.

Ann Oncol. 2013 Jan;24(1):152-60. doi: 10.1093/annonc/mds276. Epub 2012 Sep 11.

PMID:
22967994
34.

A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer.

Grønberg BH, Ciuleanu T, Fløtten Ø, Knuuttila A, Abel E, Langer SW, Krejcy K, Liepa AM, Munoz M, Hahka-Kemppinen M, Sundstrøm S.

Lung Cancer. 2012 Oct;78(1):63-9. doi: 10.1016/j.lungcan.2012.07.007. Epub 2012 Aug 20.

PMID:
22917813
35.

Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane.

Langer SW, Thougaard AV, Sehested M, Jensen PB.

Cancer Chemother Pharmacol. 2012 Feb;69(2):573-6. doi: 10.1007/s00280-011-1794-6. Epub 2011 Dec 6.

PMID:
22143379
36.

First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience.

Olsen IH, Langer SW, Jepsen I, Assens M, Federspiel B, Hasselby JP, Hansen CP, Kjaer A, Knigge U.

Acta Oncol. 2012 Jan;51(1):97-100. doi: 10.3109/0284186X.2011.582881. Epub 2011 May 26.

PMID:
21615243
37.

RE: Kesik et al: melatonin ameliorates doxorubicin-induced skin necrosis in rats.

Langer SW.

Ann Plast Surg. 2010 Nov;65(5):511; author reply 511-2. doi: 10.1097/SAP.0b013e3181f77a04. No abstract available.

PMID:
20966655
38.

Extravasation of chemotherapy.

Langer SW.

Curr Oncol Rep. 2010 Jul;12(4):242-6. doi: 10.1007/s11912-010-0110-7. Review.

PMID:
20480268
39.

A recall reaction and call for action.

Langer SW.

Onkologie. 2010;33(3):85-6. doi: 10.1159/000278722. Epub 2010 Feb 3. No abstract available.

40.

A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage.

Thougaard AV, Langer SW, Hainau B, Grauslund M, Juhl BR, Jensen PB, Sehested M.

Toxicology. 2010 Feb 28;269(1):67-72. doi: 10.1016/j.tox.2010.01.007. Epub 2010 Jan 15.

PMID:
20079798
41.

Anthracycline extravasation: a comprehensive review of experimental and clinical treatments.

Langer SW, Sehested M, Jensen PB.

Tumori. 2009 May-Jun;95(3):273-82. Review.

PMID:
19688963
42.

Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease.

Sorensen M, Lassen U, Jensen PB, Østerlind K, Jeppesen N, Jensen BB, Mellemgaard A, Rytter C, Langer SW.

J Thorac Oncol. 2008 Aug;3(8):902-6. doi: 10.1097/JTO.0b013e31817e0f58.

43.

Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.

Sorensen M, Lassen U, Palshof T, Jensen BB, Johansen J, Jensen PB, Langer SW.

Lung Cancer. 2008 May;60(2):252-8. Epub 2007 Nov 26.

PMID:
18036701
44.

Dexrazoxane for anthracycline extravasation.

Langer SW.

Expert Rev Anticancer Ther. 2007 Aug;7(8):1081-8. Review.

PMID:
18028016
45.

Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.

Langer SW, Jensen PB, Sehested M.

Cardiovasc Toxicol. 2007;7(2):151-3. Review.

PMID:
17652821
46.

Metastasizing malignant pleomorphic adenoma in a young man.

Bourke JL, Langer SW, Jensen HL.

APMIS. 2007 Jul;115(7):866-8.

PMID:
17614856
47.

Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.

Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, de Wit M, Knoblauch P, Rasmussen A, Dahlstrøm K, Jensen PB, Giaccone G.

Ann Oncol. 2007 Mar;18(3):546-50. Epub 2006 Dec 21.

PMID:
17185744
48.

Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy.

Herrstedt J, Sigsgaard TC, Nielsen HA, Handberg J, Langer SW, Ottesen S, Dombernowsky P.

Support Care Cancer. 2007 Apr;15(4):417-26. Epub 2006 Nov 9.

PMID:
17093916
49.

A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis.

Fischer BM, Mortensen J, Langer SW, Loft A, Berthelsen AK, Petersen BI, Daugaard G, Lassen U, Hansen HH.

Ann Oncol. 2007 Feb;18(2):338-45. Epub 2006 Oct 23.

PMID:
17060487
50.

PET/CT imaging in response evaluation of patients with small cell lung cancer.

Fischer BM, Mortensen J, Langer SW, Loft A, Berthelsen AK, Daugaard G, Lassen U, Hansen HH.

Lung Cancer. 2006 Oct;54(1):41-9. Epub 2006 Aug 17.

PMID:
16919841

Supplemental Content

Loading ...
Support Center